By physician referral or invitation only

SELVA: A Multicenter, Phase 3 Randomized, Double-Blind, VehicleControlled Study Evaluating the Safety and Efficacy of PTX-022 in the Treatment of Microcystic Lymphatic Malformations

This trial aims to study how effective and safe the investigational drug is at treating microcystic LM compared to a medication that looks the same but does not have the study drug (placebo).

Age & Gender

6 years ~ 99 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

United States (Nationwide)

Additional Study Information

Principal Investigator

Elizabeth Nieman
Dermatology-Research

Study Type

Clinical or Medical
Interventional

Study Topics

Child and Teen Health
Genetics and Genetic Disorders
Rare Diseases
Skin, Hair, and Nails

IRB Number

24-0156

ClinicalTrials.gov

NCT06239480

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.